Clinical Trials on Refractory Primary Myelofibrosis

Total 62264 results

Washington University School of Medicine
Takeda

Terminated

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Myelofibroses

United States
Assaf-Harofeh Medical Center

Unknown

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis (MRMF01)

Myelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ET

Israel
The University of Hong Kong

Recruiting

Ropeginterferon Alfa 2b for Early Myelofibrosis

Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage

Hong Kong
University of Chicago

Recruiting

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Chronic Myeloid Leukemia | Myelofibroses

United States
NYU Langone Health

Terminated

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibroses

United States
Centre Hospitalier Annecy Genevois

Completed

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis (Ruxo-EPO)

Myelofibrosis; Anemia
Incyte Corporation

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

Myelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...

United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
AbbVie

Terminated

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Korea, Republic of, South Africa
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany
Kartos Therapeutics, Inc.
Telios Pharma, Inc.

Recruiting

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

United States, Italy, Serbia, Poland, France, Austria, Bulgaria, Germany, Hungary, Spain
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Moderate and High Risk Myelofibrosis

China
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Institut für Klinische Krebsforschung IKF GmbH...
Celgene International II S.á.r.l.; Prof. F. Heidel, MH Hannover

Recruiting

Fedratinib in Combination With Nivolumab

Primary Myelofibrosis | Secondary Myelofibrosis

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Celgene

Completed

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (RESUME)

Primary Myelofibrosis | MPN-associated Myelofibrosis

United States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Decitabine in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

P1101 in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
AbbVie

Active, not recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

Myelofibrosis (MF)

United States, Australia, Belgium, Bulgaria, Canada, Croatia, France, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Primary Myelofibrosis | Anemia | Secondary Myelofibrosis

United States
The First Affiliated Hospital of Xiamen University

Recruiting

68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

Primary Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Myelofibrosis

China
Qilu Hospital of Shandong University

Recruiting

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Myelofibrosis

China
Geron Corporation

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Myelofibrosis

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study (FIBRAPLO)

Myelofibrosis
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Galecto Biotech AB
OPIS s.r.l

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Myelofibrosis

Germany, Italy, United States, Australia
Novartis Pharmaceuticals

Terminated

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Primary Myelofibrosis

Spain, Germany, Italy
First Affiliated Hospital of Zhejiang University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; Second Affiliated... and other collaborators

Recruiting

18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.

Myelofibrosis

China
Assiut University

Not yet recruiting

Ruxolitinib in Patients With Myelofibrosis

Myelofibrosis
University Hospital, Angers

Not yet recruiting

Clonal Architecture of ASXL1-mutated Myelofibrosis (CLONEMF)

Myelofibrosis

France
Bristol-Myers Squibb

Recruiting

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Myelofibrosis

Austria
The University of Hong Kong
Imago BioSciences,Inc.

Recruiting

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Myelofibrosis

Hong Kong
Center for International Blood and Marrow Transplant...
National Cancer Institute (NCI); National Institutes of Health (NIH); National...

Recruiting

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Myelofibrosis

United States
Karyopharm Therapeutics Inc

Active, not recruiting

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Myelofibrosis

Spain, China, Poland, United States, France, Greece, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Myelofibrosis

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Myelofibrosis

China
Stichting Hemato-Oncologie voor Volwassenen Nederland
CTI BioPharma; Dutch Cancer Society

Active, not recruiting

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF)

Myelofibrosis

Netherlands, Belgium
Qilu Hospital of Shandong University

Completed

Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis

Myelofibrosis
Geron Corporation

Completed

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Myelofibrosis

United States, France, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Korea, Republic of, Canada
CTI BioPharma
SGS S.A.

Completed

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

Myelofibrosis

Moldova, Republic of, Germany
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

Myelofibrosis

Italy, United States, Canada, Germany
M.D. Anderson Cancer Center
Celgene Corporation

Completed

A Phase II Study of CC-5013 in Myelofibrosis

Myelofibrosis

United States

Clinical Trials on Refractory Primary Myelofibrosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations